Preeclampsia: Updates in pathogenesis, definitions, and guidelines

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 6, 2016, Pages 1102-1113

  Phipps, Elizabeth ^a   Prasanna, Devika ^a   Brima, Wunnie ^b   Jim, Belinda ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; AUTOANTIBODY; CALCIUM; HEME OXYGENASE; HEPARIN; HYDRALAZINE; HYDROGEN SULFIDE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; NICARDIPINE; NIFEDIPINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ANGIOTENSIN 1 RECEPTOR; ENDOGLIN; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

COUNSELING; ECLAMPSIA; ENDOTHELIUM INJURY; HUMAN; MATERNAL AGE; MATERNAL HYPERTENSION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRACTICE GUIDELINE; PREECLAMPSIA; PRENATAL CARE; PREVALENCE; PROTEIN MISFOLDING; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION; FEMALE; IMMUNOLOGY; METABOLISM; POSTNATAL CARE; PREGNANCY; PREPREGNANCY CARE; PROTEIN FOLDING;

AUTOANTIBODIES; ENDOGLIN; FEMALE; HEME OXYGENASE (DECYCLIZING); HUMANS; HYDROGEN SULFIDE; NITRIC OXIDE; OXIDATIVE STRESS; POSTNATAL CARE; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PRECONCEPTION CARE; PREGNANCY; PROTEIN FOLDING; RECEPTOR, ANGIOTENSIN, TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84992366827     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12081115     Document Type: Review

References (104)

1. Roberts JM, Hubel CA: The two stage model of preeclampsia: Variations on the theme. Placenta 30[Suppl A]: S32-S37, 2009
2. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK: Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 161: 1200-1204, 1989
3. Sircar M, Thadhani R, Karumanchi SA: Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 24: 131-138, 2015
4. Gilbert JS, Babcock SA, Granger JP: Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50: 1142-1147, 2007
5. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A: Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71: 977-984, 2007
6. Kaufmann P, Black S, Huppertz B: Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 69: 1-7, 2003
7. Brosens I: A study of the spiral arteries of the decidua basalis in normotensive and hypertensive pregnancies. JObstet Gynaecol Br Commonw 71: 222-230, 1964
8. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003
9. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649, 2006
10. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, Thadhani R, Karumanchi SA: Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 32: 189-201, 2013
11. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S: Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. NEngl JMed 374: 13-22, 2016
12. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P: Angiogenic factors in superimposed preeclampsia: A longitudinal study of women with chronic hypertension during pregnancy. Hypertension 59: 740-746, 2012
13. Rolfo A, Attini R, Nuzzo AM, Piazzese A, Parisi S, Ferraresi M, Todros T, Piccoli GB: Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 83: 177-181, 2013
14. Masuyama H, Nobumoto E, Okimoto N, Inoue S, Segawa T, Hiramatsu Y: Superimposed preeclampsia in women with chronic kidney disease. Gynecol Obstet Invest 74: 274-281, 2012
15. de Jesus GR, de Jesus NR, Levy RA, Klumb EM: The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis. Lupus 23: 1299-1301, 2014
16. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T: Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 27: 903-913, 2016
17. Bainbridge SA, Farley AE, McLaughlin BE, Graham CH, Marks GS, Nakatsu K, Brien JF, Smith GN: Carbon monoxide decreases perfusion pressure in isolated human placenta. Placenta 23: 563-569, 2002
18. Zhao H, Wong RJ, Doyle TC, Nayak N, Vreman HJ, Contag CH, Stevenson DK: Regulation of maternal and fetal hemodynamics by heme oxygenase in mice. Biol Reprod 78: 744-751, 2008
19. Lyall F, Barber A, Myatt L, Bulmer JN, Robson SC: Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function. FASEB J 14: 208-219, 2000
20. McCaig D, Lyall F: Inhibitors of heme oxygenase reduce invasion of human primary cytotrophoblast cells in vitro. Placenta 30: 536-538, 2009
21. Ahmed A, Rahman M, Zhang X, Acevedo CH, Nijjar S, Rushton I, Bussolati B, St John J: Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation. Mol Med 6: 391-409, 2000
22. Dulak J, Deshane J, Jozkowicz A, Agarwal A: Heme oxygenase-1 and carbon monoxide in vascular pathobiology: Focus on angiogenesis. Circulation 117: 231-241, 2008
23. Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK: Effect of heme oxygenase-1 deficiency on placental development. Placenta 30: 861-868, 2009
24. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S: Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103: 129-135, 1999
25. Linzke N, Schumacher A, Woidacki K, Croy BA, Zenclussen AC: Carbon monoxide promotes proliferation of uterine natural killer cells and remodeling of spiral arteries in pregnant hypertensive heme oxygenase-1 mutant mice. Hypertension 63: 580-588, 2014
26. Barber A, Robson SC, Myatt L, Bulmer JN, Lyall F: Heme oxygenase expression in human placenta and placental bed: Reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction. FASEB J 15: 1158-1168, 2001
27. Farina A, Sekizawa A, De Sanctis P, Purwosunu Y, Okai T, Cha DH, Kang JH, Vicenzi C, Tempesta A, Wibowo N, Valvassori L, Rizzo N: Gene expression in chorionic villous samples at 11 weeks’ gestation from women destined to develop preeclampsia. Prenat Diagn 28: 956-961, 2008
28. Aoki Y, Yamamoto T, Fumihisa C, Nakamura A, Asanuma A, Suzuki M: Effect on the production of soluble endoglin from human choriocarcinoma cells by preeclampsia sera. Am J Reprod Immunol 67: 413-420, 2012
29. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A: Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115: 1789-1797, 2007
30. Conde-Agudelo A, Althabe F, Belizán JM, Kafury-Goeta AC: Cigarette smoking during pregnancy and risk of preeclampsia: A systematic review. AmJObstet Gynecol 181: 1026-1035, 1999
31. Sidle EH, Casselman R, Smith GN: Effect of cigarette smoke on placental antioxidant enzyme expression. Am J Physiol Regul Integr Comp Physiol 293: R754-R758, 2007
32. Mehendale R, Hibbard J, Fazleabas A, Leach R: Placental angiogenesis markers sFlt-1 and PlGF: Response to cigarette smoke. Am J Obstet Gynecol 197: 363.e1-363.e5, 2007
33. Baum M, Schiff E, Kreiser D, Dennery PA, Stevenson DK, Rosenthal T, Seidman DS: End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia. Am J Obstet Gynecol 183: 900-903, 2000
34. Kreiser D, Baum M, Seidman DS, Fanaroff A, Shah D, Hendler I, Stevenson DK, Schiff E, Druzin ML: End tidal carbon monoxide levels are lower in women with gestational hypertension and preeclampsia. J Perinatol 24: 213-217, 2004
35. Jim B, Bramham K, Maynard SE, Hladunewich MA: Pregnancy and kidney disease. Nephrol Self Assess Program 15: XXX-, 2016
36. Zhao W, Zhang J, Lu Y, Wang R: The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 20: 6008-6016, 2001
37. Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, Baily J, Miller MR, Cudmore M, Hadoke PW, Wang R, Gratacós E, Buhimschi IA, Buhimschi CS, Ahmed A: Dysregulation of hydrogen sulfide producing enzyme cystathionine g-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation 127: 2514-2522, 2013
38. Holwerda KM, Burke SD, Faas MM, Zsengeller Z, Stillman IE, Kang PM, van Goor H, McCurley A, Jaffe IZ, Karumanchi SA, Lely AT: Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol 25: 717-725, 2014
39. Holwerda KM, Bos EM, Rajakumar A, Ris-Stalpers C, van Pampus MG, Timmer A, Erwich JJ, Faas MM, van Goor H, Lely AT: Hydrogen sulfide producing enzymes in pregnancy and preeclampsia. Placenta 33: 518-521, 2012
40. Cindrova-Davies T, Herrera EA, Niu Y, Kingdom J, Giussani DA, Burton GJ: Reduced cystathionine g-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: Hydrogen sulfide as a placental vasodilator. Am J Pathol 182: 1448-1458, 2013
41. Snijder PM, Frenay AR, Koning AM, Bachtler M, Pasch A, Kwakernaak AJ, van den Berg E, Bos EM, Hillebrands JL, Navis G, Leuvenink HG, van Goor H: Sodium thiosulfate attenuates angiotensin II-induced hypertension, proteinuria and renal damage. Nitric Oxide 42: 87-98, 2014
42. Selk N, Rodby RA: Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy. Semin Dial 24: 85-88, 2011
43. Brucculeri M, Cheigh J, Bauer G, Serur D: Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 18: 431-434, 2005
44. Quillon A, Fromy B, Debret R: Endothelium microenvironment sensing leading to nitric oxidemediated vasodilation: A reviewof nervous and biomechanical signals. NitricOxide 45: 20-26, 2015
45. Lowe DT: Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 4: 441-458, 2000
46. Dai B, Liu T, Zhang B, Zhang X, Wang Z: The polymorphism for endothelial nitric oxide synthase gene, the level of nitric oxide and the risk for pre-eclampsia: A meta-analysis. Gene 519: 187-193, 2013
47. Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F: Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 34: 957-963, 2008
48. Sankaralingam S, Xu H, Davidge ST: Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia. Cardiovasc Res 85: 194-203, 2010
49. Kulandavelu S, Whiteley KJ, Qu D, Mu J, Bainbridge SA, Adamson SL: Endothelial nitric oxide synthase deficiency reduces uterine blood flow, spiral artery elongation, and placental oxygenation in pregnant mice. Hypertension 60: 231-238, 2012
50. Burton GJ, Jauniaux E: Placental oxidative stress: Frommiscarriage to preeclampsia. J Soc Gynecol Investig 11: 342-352, 2004
51. Myatt L, Cui X: Oxidative stress in the placenta. HistochemCell Biol 122: 369-382, 2004
52. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC: AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632-1639, 2003
53. Raijmakers MT, Peters WH, Steegers EA, Poston L: NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. Placenta 25 [Suppl A]: S85-S89, 2004
54. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Pre-eclampsia (VIP) Trial Consortium: Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): Randomised placebo-controlled trial. Lancet 367: 1145-1154, 2006
55. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103: 945-952, 1999
56. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr., Ryan MJ, Dechend R: Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: Role of endothelin-1. Hypertension 54: 905-909, 2009
57. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 14: 855-862, 2008
58. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y: Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 100: 88-95, 2007
59. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 121: 436-444, 2010
60. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T: Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 91: 2424-2427, 2006
61. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: Correlation with disease severity. Hypertension 55: 386-393, 2010
62. Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, Bernstein IM, Glabe CG, Buhimschi CS: Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med 6: 245ra92, 2014
63. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 175: 1365-1370, 1996
64. von Dadelszen P, Magee LA, Roberts JM: Subclassification of preeclampsia. Hypertens Pregnancy 22: 143-148, 2003
65. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683, 2004
66. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y: Different profiles of circulating angiogenic factors and adipocytokines between early-and late-onset pre-eclampsia. BJOG 117: 314-320, 2010
67. Papageorghiou AT, Campbell S: First trimester screening for preeclampsia. Curr Opin Obstet Gynecol 18: 594-600, 2006
68. Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH: Second-trimester uterine artery Doppler screening in unselected populations: A review. J Maternal Fetal Neonatal Med 12: 78-88, 2002
69. Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group: Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 18: 441-449, 2001
70. Aardema MW, Oosterhof H, Timmer A, van Rooy I, Aarnoudse JG: Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses. Placenta 22: 405-411, 2001
71. Espinoza J, Romero R, Mee Kim Y, Kusanovic JP, Hassan S, Erez O, Gotsch F, Than NG, Papp Z, Jai Kim C: Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med 34: 447-458, 2006
72. Voigt HJ, Becker V: Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med 20: 139-147, 1992
73. Mongraw-Chaffin ML, Cirillo PM, Cohn BA: Preeclampsia and cardiovascular disease death: Prospective evidence from the child health and development studies cohort. Hypertension 56: 166-171, 2010
74. Paruk F, Moodley J: Maternal and neonatal outcome in early-and late-onset pre-eclampsia. Semin Neonatol 5: 197-207, 2000
75. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B: The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 189: 1173-1177, 2003
76. Murphy DJ, Stirrat GM: Mortality and morbidity associated with early-onset preeclampsia. Hypertens Pregnancy 19: 221-231, 2000
77. Ness RB, Sibai BM: Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 195: 40-49, 2006
78. Amaral LM, Cunningham MW Jr., Cornelius DC, LaMarca B: Preeclampsia: Long-term consequences for vascular health. Vasc Health Risk Manag 11: 403-415, 2015
79. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 365: 785-799, 2005
80. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V: Preeclampsia and future cardiovascular risk among women: A review. J Am Coll Cardiol 63: 1815-1822, 2014
81. Bellamy L, Casas JP, Hingorani AD, Williams DJ: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. BMJ 335: 974, 2007
82. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR: Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 114: 961-970, 2009
83. Lin YS, Tang CH, Yang CY, Wu LS, Hung ST, Hwa HL, Chu PH: Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan. Am J Cardiol 107: 325-330, 2011
84. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM: Preeclampsia and the risk of end-stage renal disease. N Engl J Med 359: 800-809, 2008
85. Al-Nasiry S, Ghossein-Doha C, Polman SE, Lemmens S, Scholten RR, Heidema WM, Spaan JJ, Spaanderman ME: Metabolic syndrome after pregnancies complicated by preeclampsia or small-for-gestational-age: A retrospective cohort. BJOG 122: 1818-1823, 2015
86. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, Franx A, de Groot CJ, Koster MP: Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension 65: 600-606, 2015
87. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS: Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol 124: 771-781, 2014
88. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183: S1-S22, 2000
89. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy: Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122: 1122-1131, 2013
90. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP)Working Group: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 4: 105-145, 2014
91. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, Paech MJ, Said JM; Society of Obstetric Medicine of Australia and New Zealand: The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy
92. Aust N Z J Obstet Gynaecol 55: 11-16, 2015
93. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA: The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 4: 97-104, 2014
94. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Singer J, Gafni A, Gruslin A, Helewa M, Hutton E, Lee SK, Lee T, Logan AG, Ganzevoort W, Welch R, Thornton JG, Moutquin JM: Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 372: 407-417, 2015
95. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ: Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 1: CD002252, 2007
96. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA: Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354: 2443-2451, 2006
97. Li DK, Yang C, Andrade S, Tavares V, Ferber JR: Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: A retrospective cohort study. BMJ 343: d5931, 2011
98. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 6: CD001059, 2014
99. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS; ACTS Study Group: Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 354: 1796-1806, 2006
100. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Gigue` re Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol 116: 402-414, 2010
101. Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG: Low-dose aspirin for prevention of morbidity andmortality from preeclampsia: A systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 160: 695-703, 2014
102. Dodd JM, McLeod A, Windrim RC, Kingdom J: Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 7: CD006780, 2013
103. Lucas MJ, Leveno KJ, Cunningham FG: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 333: 201-205, 1995
104. The Eclampsia Trial Collaborative Group: Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 345: 1455-1463, 1995